Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

Share Price Information for Tissue Regenix Group (TRX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 65.50
Bid: 64.00
Ask: 67.00
Change: 0.00 (0.00%)
Spread: 3.00 (4.688%)
Open: 65.50
High: 65.50
Low: 65.50
Prev. Close: 65.50
TRX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Contract win - hospitality

13 Jun 2005 07:01

XN Checkout Holdings PLC11 June 2005 Press Release 13 June 2005 XN Checkout Holdings Plc Caffe Nero chooses XN Checkout EpoS After extensive trials and pilot installations Caffe Nero have chosen XNCheckout Holdings Plc (AIM:XNC), a market leader of Electronic Point of sale ("EPoS") solutions to the leisure, retail and hospitality markets to provide anestate wide EPoS system. XN Checkout are providing their latest WEB based Hospitality EPoS technologywhich includes sales, promotions, stock and real time business alerts andreporting. The Contract, is worth an estimated £3 million over the next fiveyears. The rollout commences in June 2005 and will carry on into next year. Caffe Nero is currently the largest independent coffee retailer in the UK withover 220 stores stretching from Brighton to Glasgow. To date the company hasgrown at the rate of over 40 stores per annum. The web based installations provide Caffe Nero with rapid sales EPoS systemsthrough colour touch screen terminals, as well as stock and outlet reporting. Gerry Ford, CEO and Chairman of Caffe Nero said: "We have had a long quest tofind the right EPoS solution from the right partner to support the growth of ourbusiness. XN Checkout have provided the understanding of our business andtailored their system to help us meet our business goals. Having a system thatsupports our customer service, particularly with our peaks in trade whilstproviding real time data was always going to be a challenge, which XN Checkouthave met." Ed Dayan, CEO of XN Checkout said: "We are delighted to have been chosen byCaffe Nero as their EPoS partner. Their requirements are challenging and we havedemonstrated the quality of our team to understand our customers business andthe benefits that accrue from our web based solutions. Caffe Nero are a dynamicand highly successful business which we are proud to be associated with." XN Checkout is subject to a Recommended Offer by Evolution Securities Limited onbehalf of Torex Retail Plc for the entire share capital of XN Checkout HoldingsPlc as announced on 10 June 2005. On behalf of Torex Retail, Evolution willoffer to acquire all of the XN Checkout Shares on the following basis: for each XN Checkout Share 2.547 New Torex Shares and so in proportion for any other number of XN Checkout Shares held. Based onthe Closing Price of 104p per Torex Share on the business day immediately priorto the date of this announcement, the Offer values each XN Checkout Share atapproximately 264.9 pence. This represents a premium of approximately 8.6 percent. over the middle market price of an XN Checkout Share of 244p at the closeof business on 3 June 2005, being the last business day before the announcementon 6 June 2005 that it was in bid discussions. Ends For further information:XN Checkout Holdings PlcEd Dayan, Chief Executive +44 (0) 1582 869 610edayan@xncheckout.com www.xncheckout.com Daniel Stewart & Co. Ruari McGirr Tel: +44 (0) 20 7374 6789ruari.mcgirr@danielstewart.co.uk www.danielstewart.co.uk Media enquiries:AbchurchAriane Comstive / Henry Harrison-Topham Tel: +44 (0) 20 7398 7700ariane.comstive@abchurch-group.com www.abchurch-group.com Notes to editors XN Checkout Holdings plc XN Checkout is the market leader for EPOS hardware and software solutions intothe UK managed pub and bar sector, with over 4,000 systems installed. TheCompany has been successful in broadening its target markets to includerestaurants, hotels, retail shops and gaming hardware and software solutions. Co-founded in 1982 by the chief executive Ed Dayan, the Company created thefirst touch-till system for a pub and has over 20 years' experience ofmanufacturing hardware and developing software solutions for the EPOS market,resulting in XN Checkout technology remaining at the forefront of the industry.The Company's technology is now being used in the hotel, gaming, retail and thefast-growing SME hospitality sectors. As an innovator of web-based EPOS systems, XN Checkout benefits fromlong-standing client relationships with leading leisure and hospitalitybusinesses including Mitchells & Butlers, Wolverhampton & Dudley, the SpiritGroup, Young's and Stena Line. More recent customers include Cafe Rouge, TheParamount Group of Hotels, and Gala Group. The Company employs 178 people, isbased in Dunstable, Bedfordshire and has offices in Singapore, Malaysia, SouthKorea, Australia, South Africa, the USA and Germany. For further information please visit www.xncheckout.com Caffe Nero Group Plc Caffe Nero Group Plc was founded in 1997 when five sites were acquired by asyndicate of investors. The name Caffe Nero was retained for the original sitesbut an entirely new brand was created centering around an authentic Europeancoffee house concept and serving gourmet quality coffee and deli food products.Caffe Nero is currently the largest independent coffee retailer in the UK, withover 220 Caffe Nero stores from Brighton to Glasgow. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
14th Jun 20247:00 amRNSBuilding purchase
25th Apr 20242:27 pmRNSResult of AGM
10th Apr 20247:15 amEQSHardman & Co Research on Tissue Regenix (TRX): Six consecutive periods of >20% growth
5th Apr 20243:52 pmRNSHolding(s) in Company
19th Mar 20247:00 amRNSFinal results for the year ended 31 December 2023
1st Mar 20247:00 amRNSNotice of Results
6th Feb 20247:00 amRNSFirst EU shipment & new distributor agreements
29th Jan 20243:02 pmRNSHolding(s) in Company
25th Jan 20247:00 amRNSTrading update for 2023
23rd Jan 20245:24 pmRNS2023 LTIP Grant
22nd Nov 20234:36 pmRNSHolding(s) in Company
30th Oct 20237:00 amRNSHPRA approval & distribution agreement in Spain
18th Sep 202310:40 amEQSHardman & Co Research on Tissue Regenix (TRX): Continuing postive momentum 1H'23
15th Sep 20234:30 pmRNSDirector/PDMR Shareholding
5th Sep 20237:01 amRNSNew sports medicine product launch
5th Sep 20237:00 amRNSInterim results
31st Aug 20231:45 pmRNSExercise of Options and Total Voting Rights
21st Aug 20237:00 amRNSNotice of interim results
17th Jul 20237:00 amRNSHalf-Year Trading Update
10th Jul 20237:00 amRNSDistribution agreement for OrthoPure® XT in the UK
25th May 20237:00 amRNSDistribution agreement with Australian Allografts
9th May 202312:00 pmRNSHolding(s) in Company
27th Apr 202312:35 pmRNSResult of AGM, Share Reorganisation &TVR
18th Apr 20237:00 amRNSProposed Share Reorganisation Timetable
5th Apr 20232:55 pmEQSHardman & Co Research on Tissue Regenix (TRX): Turning profitable and cash-generative
5th Apr 20237:00 amRNSCEO and CFO Share Purchases
30th Mar 20237:00 amRNSHolding(s) in Company
21st Mar 20237:00 amRNSFinal results for the year ended 31 December 2022
6th Mar 20237:00 amRNSNotice of results and Investor presentation
31st Jan 20237:01 amRNSTrading update for 2022
31st Jan 20237:00 amRNSChange of Adviser
18th Jan 202310:06 amRNSHolding(s) in Company
18th Jan 20237:00 amRNSChinese distribution agreement for OrthoPure® XT
7th Dec 20227:00 amRNSProduct launch in dCELL® division
22nd Nov 20227:00 amRNSDistribution agreement - OrthoPure® XT in Germany
14th Nov 20226:05 pmRNSHolding(s) in Company
7th Nov 20222:35 pmRNSHolding(s) in Company
29th Sep 202210:13 amRNSDirector/PDMR Shareholding
27th Sep 20227:15 amEQSHardman & Co Research on Tissue Regenix (TRX): Operating leverage
7th Sep 20227:00 amRNSHalf-year Report
22nd Aug 20223:31 pmRNSHolding(s) in Company
18th Aug 20225:36 pmRNSHolding(s) in Company
18th Aug 20222:10 pmRNSHolding(s) in Company
11th Aug 20224:30 pmEQSHardman & Co Research: Q&A on Tissue Regenix Group plc: Significantly undervalued which should correct
11th Aug 202212:46 pmRNSHolding(s) in Company
11th Aug 202212:17 pmRNSHolding(s) in Company
11th Aug 20227:00 amRNSConfirmation of Interim Results
5th Aug 20223:19 pmRNSHolding(s) in Company
1st Aug 20223:14 pmRNSHolding(s) in Company
19th Jul 20222:30 pmEQSHardman & Co Research : Tissue Regenix (TRX): Strong 1H’22 sales suggest upside potential

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.